AmpliPhi Biosciences and C3J Therapeutics Agree to Merge January 4, 2019 Transaction to result in NYSE American-listed company focused on development of precisely-targeted bacteriophage therapeutics Merger combines AmpliPhi’s extensive phage library and Phase 1/2-ready asset with C3J’s expertise in synthetic phage and broad preclinical pipeline $10 million to be invested by … Continued
C3J Therapeutics Bolsters Antimicrobial R&D Program; Acquires Engineered Bacteriophage Assets from Synthetic Genomics February 28, 2018 LOS ANGELES, and LA JOLLA, CALIF., February 28, 2018 — C3J Therapeutics, Inc., (C3J) a private biotechnology company focused on the development of novel targeted antimicrobials, and Synthetic Genomics, Inc., (SGI) a leader in designing and programming biology for desired … Continued
C3J Therapeutics Unveils Development of Two New Product Formulations of Lead Candidate C16G2 for Prevention of Dental Caries December 12, 2016 LOS ANGELES, California — December 12, 2016 — C3J Therapeutics, Inc., a private, clinical stage biotechnology company focused on the development and commercialization of novel therapeutics aimed at reengineering the human microbiome, today announced the development of two new formulations … Continued